Abstract
Leishmaniasis is one of the most common neglected tropical diseases (NTD), and is originated in over 98 countries, affecting about 12 million people every year, which is diversified based upon the parasite species. Its genetic inheritance and host immunity with over more than one billion people would be at severe risk of disease. There is no specific treatment available for leishmaniasis presently, hence an urgent need for the novel and effective therapies and drugs are highly warranted. The current review provides an update for the synthesis of various heterocyclic molecules, schiff bases and amide linkages which showed excellent potential against leishmaniasis and its various causative species. This review is based on last five-year literature reports and will provide an idea for medicinal chemist for new drug development to eradicate leishmaniasis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
